<!DOCTYPE html>
<html lang="en" style="--theme-color: #262626; --link-color: #262626;">
<head>
  <meta charset="UTF-8">
  <title>医学翻译学习-verubecestat治疗前驱期阿尔茨海默病的随机试验 - 王楠鑫|Curtis_一个医学译者的前后左右</title>

  <link rel="icon" href="">
<!-- <link href="https://cdn.jsdelivr.net/npm/remixicon@2.5.0/fonts/remixicon.css" rel="stylesheet"> -->
<link rel="alternate" type="application/atom+xml" title="王楠鑫|Curtis_一个医学译者的前后左右 - Atom Feed" href="https://airmedtrans.com/atom.xml">

  

  
  <!-- Global site tag (gtag.js) - Google Analytics -->
  <!-- <script async src="https://www.googletagmanager.com/gtag/js?id=G-NFCRR8Q57W"></script>
  <script>
    window.dataLayer = window.dataLayer || [];
    function gtag(){dataLayer.push(arguments);}
    gtag('js', new Date());
  </script> -->
  <script async src='https://www.google-analytics.com/analytics.js'></script>



  <script>
    window.ga=window.ga||function(){(ga.q=ga.q||[]).push(arguments)};ga.l=+new Date;
    ga('create', 'UA-182385326-1');
    ga('set', 'dimension1', 'site/cbS9tMKNT');
    ga('set', 'dimension2', 'post/fc40JvTxV');
    ga('send', 'pageview');
    // gtag('set', {
    //   'custom_map': {
    //     'dimension1': 'siteId',
    //     'dimension2': 'postId',
    //   }
    // })

    // gtag('config', 'G-NFCRR8Q57W', {
    //   'siteId': 'site/cbS9tMKNT',
    //   'postId': 'post/fc40JvTxV',
    // });
  </script>





  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <meta name="description" content="关于“verubecestat治疗前驱期阿尔茨海默病的随机试验”一文医学翻译摘要学习情况，记录于此。
Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease 

...">

  <meta property="og:title" content="医学翻译学习-verubecestat治疗前驱期阿尔茨海默病的随机试验 - 王楠鑫|Curtis_一个医学译者的前后左右">
  <meta property="og:description" content="关于“verubecestat治疗前驱期阿尔茨海默病的随机试验”一文医学翻译摘要学习情况，记录于此。
Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease 

...">
  
  <meta property="og:url" content="https://airmedtrans.com/swbDHcPQ1/">
  <meta property="og:site_name" content="王楠鑫|Curtis_一个医学译者的前后左右">

  <meta name="twitter:card" content="summary_large_image">
  <meta name="twitter:image:alt" content="医学翻译学习-verubecestat治疗前驱期阿尔茨海默病的随机试验">

  <meta name="gridea:post_id" content="fc40JvTxV">

  <link rel="canonical" href="https://airmedtrans.com/swbDHcPQ1">
  <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/highlight.js@10.0.3/styles/a11y-light.css">
  
  <link rel="stylesheet" href="//cdn.jsdelivr.net/npm/@gridea/theme@1.0.8/css/main.css">

</head>
<body>
  
    
  
  <div id="page">
    <div class="mb-16 sticky top-0 z-20 bg-white">
  <header class="py-4 flex items-baseline justify-between max-w-2xl mx-auto px-2">
    <h1 class="text-lg text-center font-medium px-4 md:px-0 flex items-center">
      <div class="site-logo-text font-normal">王</div>
      <a href="/">王楠鑫|Curtis_一个医学译者的前后左右</a>
    </h1>
    <div class="hidden sm:flex justify-center">
      
        
        <a
          href="https://airmedtrans.com/aboutme"
          class="mx-2 text-base border-b border-transparent"
          target="_blank"
        >关于我</a>
        
          <span class="text-gray-200">/</span>
        
      
        
        <a
          href="https://airmedtrans.com/contact me"
          class="mx-2 text-base border-b border-transparent"
          target="_blank"
        >联系我</a>
        
      
    </div>
    <div class="flex sm:hidden py-2 px-4 text-center cursor-pointer" @click="openMenu = true">
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" width="24" height="24"><path fill="none" d="M0 0h24v24H0z"/><path d="M3 4h18v2H3V4zm0 7h18v2H3v-2zm0 7h18v2H3v-2z"/></svg>
    </div>
  </header>

  <div class="fixed top-0 right-0 bottom-0 left-0 bg-white hidden" :style="{
    display: openMenu ? 'block !important' : 'none',
  }" v-if="openMenu">
    <div class="py-4 px-2 flex justify-end" @click="openMenu = false">
      <div class="flex py-2 px-4 text-center cursor-pointer">
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" width="24" height="24"><path fill="none" d="M0 0h24v24H0z"/><path d="M12 10.586l4.95-4.95 1.414 1.414-4.95 4.95 4.95 4.95-1.414 1.414-4.95-4.95-4.95 4.95-1.414-1.414 4.95-4.95-4.95-4.95L7.05 5.636z"/></svg>
      </div>
    </div>
    <div class="flex flex-col p-4">
      
        
        <a
          href="https://airmedtrans.com/aboutme"
          class="mx-2 my-4 text-base border-b border-transparent"
          target="_blank"
        >关于我</a>
      
        
        <a
          href="https://airmedtrans.com/contact me"
          class="mx-2 my-4 text-base border-b border-transparent"
          target="_blank"
        >联系我</a>
      
    </div>
  </div>
</div>
    <div class="border-b border-gray-200">
      <div class="max-w-2xl mx-auto px-6 md:px-2">
        <div class="my-24 text-center">
          <h1 class="text-2xl font-bold">医学翻译学习-verubecestat治疗前驱期阿尔茨海默病的随机试验</h1>
          <div class="post-title-bar mx-auto rounded mt-4"></div>
          <div class="text-gray-400 mt-4">2020.10.16</div>
          <div class="flex justify-center mt-4">
            
          </div>
        </div>
      </div>
    </div>
    <div id="sticky-bar" class="w-full sticky top-0 z-10 bg-white" style="height: 64px;"></div>
    <div class="p-4 md:p-16 bg-white">
      <div class="max-w-2xl mx-auto px-4 flex relative">
        <section class="post-content flex-1 default-post-content max-w-2xl">
          <div v-pre>
            <p>关于“verubecestat治疗前驱期阿尔茨海默病的随机试验”一文医学翻译摘要学习情况，记录于此。</p>
<p><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1812840?query=nejmyxqy">Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease </a></p>
<!--more-->
<hr>
<blockquote>
<p><strong>背景</strong></p>
<p>BACKGROUND</p>
<p>对于在痴呆出现之前改变脑内淀粉样蛋白沉积的药物，前驱期阿尔茨海默病为其提供了药效检验机会。</p>
<p>Prodromal Alzheimer’s disease offers an opportunity <strong>to</strong> test the effect of drugs <strong>that</strong> modify the deposition of amyloid <strong>in</strong> the brain <strong>before</strong> the onset of dementia.</p>
</blockquote>
<p>笔记：</p>
<ul>
<li>Prodromal Alzheimer’s disease	前驱期阿尔茨海默病</li>
</ul>
<blockquote>
<p>verubecestat是一种口服的淀粉样前体蛋白β位点裂解酶-1（BACE-1）抑制剂，能够阻断淀粉样蛋白β（Aβ）的产生。</p>
<p>Verubecestat is an <strong>orally administered</strong> β-site amyloid precursor protein–cleaving enzyme 1 (BACE-1) inhibitor that blocks production of amyloid-beta (Aβ).</p>
</blockquote>
<p>笔记：</p>
<ul>
<li>β-site amyloid precursor protein–cleaving enzyme 1 (BACE-1) inhibitor	 淀粉样前体蛋白β位点裂解酶-1（BACE-1）抑制剂</li>
</ul>
<blockquote>
<p>在对阿尔茨海默病所致轻至中度痴呆患者开展的一项试验中，本药未能阻止疾病的临床进展。</p>
<p>The drug did not prevent clinical progression in a trial involving patients with <strong>mild-to-moderate dementia</strong> due to Alzheimer’s disease.</p>
</blockquote>
<p>笔记：</p>
<ul>
<li>clinical progression	临床进展</li>
<li>mild-to-moderate dementia	轻至中度痴呆</li>
</ul>
<blockquote>
<p><strong>方法</strong></p>
<p>METHODS</p>
<p>我们开展了一项为期104周的随机、双盲、安慰剂对照试验，在有记忆障碍和脑内淀粉样蛋白水平升高，但病情不符合痴呆定义的患者中比较了每日12 mg和40 mg剂量的verubecestat与安慰剂。</p>
<p>We conducted a randomized, double-blind, placebo-controlled, 104-week trial to evaluate verubecestat at doses of 12 mg and 40 mg per day, as compared with placebo, in patients who had memory impairment and elevated brain amyloid levels but whose condition did not meet the case definition of dementia.</p>
</blockquote>
<p>笔记：</p>
<ul>
<li>句子结构很经典</li>
</ul>
<blockquote>
<p>主要结局是临床痴呆评定量表-总分（Clinical Dementia Rating Scale - Sum of Boxes [CDR-SB]；评分范围为0～18分，较高的评分表示较差的认知和日常功能）从基线至第104周的变化。</p>
<p>The primary outcome was the change from baseline to week 104 in the score on the Clinical Dementia Rating Scale–Sum of Boxes (CDR-SB; scores range from 0 to 18, with higher scores indicating worse cognition and daily function).</p>
</blockquote>
<p>笔记：</p>
<ul>
<li>
<p>主要结局	primary outcome</p>
</li>
<li>
<p>临床痴呆评定量表	Clinical Dementia Rating Scale}</p>
</li>
</ul>
<blockquote>
<p>次要结局包括对认知和日常功能的其他评估。</p>
<p>Secondary outcomes included other assessments of cognition and daily function.</p>
</blockquote>
<blockquote>
<p><strong>结果</strong></p>
<p>RESULTS</p>
</blockquote>
<blockquote>
<p>纳入1,454例患者后，本试验因无效（futility）而终止；485例患者被分配接受12 mg/d剂量的verubecestat治疗（12 mg组），484例接受40 mg/d剂量的verubecestat治疗（40 mg组），485例接受安慰剂治疗。</p>
<p><strong>The trial was terminated for</strong> futility after 1454 patients had been enrolled; 485 had been assigned to receive verubecestat at a dose of 12 mg per day (the 12-mg group), 484 <strong>to</strong> receive verubecestat at a dose of 40 mg per day (the 40-mg group), and 485 <strong>to</strong> receive placebo..</p>
</blockquote>
<p>笔记：</p>
<ul>
<li>加粗to是be assigned to 的省略</li>
</ul>
<blockquote>
<p>各组分别共有234例患者、231例患者和239例患者完成了104周的试验治疗方案。</p>
<p>A total of 234 patients, 231 patients, and 239 patients per group, respectively, completed 104 weeks of the trial regimen.</p>
</blockquote>
<blockquote>
<p>在12 mg组、40 mg组和安慰剂组中，CDR-SB评分从基线至第104周的估计平均变化分别为1.65、2.02和1.58（12 mg组和安慰剂组之间的比较，<em>P</em>=0.67；40 mg组和安慰剂组之间的比较，<em>P</em>=0.01），这些结果提示，较大剂量组的结局比安慰剂组差。</p>
<p>The estimated mean change from baseline to week 104 in the CDR-SB score was 1.65 in the 12-mg group, 2.02 in the 40-mg group, and 1.58 in the placebo group (P=0.67 for the comparison between the 12-mg group and the placebo group and P=0.01 for the comparison between the 40-mg group and the placebo group), suggesting a worse outcome in the higher-dose group than in the placebo group.</p>
</blockquote>
<p>笔记：</p>
<ul>
<li>suggesting后面的那个比较级挺有意思的</li>
</ul>
<blockquote>
<p>在12 mg组、40 mg组和安慰剂组中，进展至阿尔茨海默病所致痴呆的发生率分别为24.5起事件/100患者-年、25.5起事件/100患者-年和19.3起事件/100患者-年（40 mg *vs.*安慰剂的风险比，1.38；97.51%置信区间，1.07～1.79，未进行多重比较校正），安慰剂的结果较好。</p>
<p>The estimated rate of progression to dementia due to Alzheimer’s disease was 24.5, 25.5, and 19.3 events per 100 patient-years in the 12-mg group, the 40-mg group, and the placebo group, respectively (hazard ratio for 40 mg vs. placebo, 1.38; 97.51% confidence interval, 1.07 to 1.79, not adjusted for multiple comparisons), favoring placebo.</p>
</blockquote>
<blockquote>
<p>verubecestat组的不良事件发生率高于安慰剂组。</p>
<p>Adverse events were more common in the verubecestat groups than in the placebo group.</p>
</blockquote>
<p>笔记：</p>
<ul>
<li>比较级的结构和之前suggesting后的结构一致</li>
</ul>
<blockquote>
<p><strong>结论</strong></p>
<p>CONCLUSIONS</p>
<p>在前驱期阿尔茨海默病患者中，verubecestat未改善痴呆的临床评分，并且一些指标提示，verubecestat组患者的认知和日常功能比安慰剂组患者差（由默沙东公司资助；在ClinicalTrials.gov注册号为NCT01953601）。</p>
<p>Verubecestat did not improve clinical ratings of dementia among patients with prodromal Alzheimer’s disease, and some measures suggested that cognition and daily function were worse among patients who received verubecestat than among those who received placebo. (Funded by Merck Sharp &amp; Dohme; ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT01953601">NCT01953601</a>.)</p>
</blockquote>
<p>笔记：</p>
<ul>
<li>NEJM的官方译文似乎从来没有在标点上出现与原文不一致的情况。这或许是他们风格指南的要求之一</li>
<li>比较级的用法变了，甚感欣慰</li>
</ul>

          </div>
          <div class="py-4 text-gray-600 flex items-center justify-between">
            <div class="">
              <div class="text-sm text-gray-300">最后更新于: </div>
              <div class="text-base font-medium">2020.10.16</div>
            </div>
            <!-- <div class="flex items-center text-sm text-gray-600">
              <i class="ri-eye-line"></i> <span class="ml-2">{{ views }}</span>
            </div> -->
          </div>
          <div>
            <div id="disqus_thread"></div>
          </div>
        </section>
        
      </div>
    </div>
    <div class="py-8 text-gray-300 text-center border-t border-gray-200">
  Powered by Gridea
</div>
  </div>

  <script src="//cdn.jsdelivr.net/npm/vue@2.6.11"></script>
  
  <script src="//cdn.jsdelivr.net/npm/@gridea/theme@1.0.8/js/main.js"></script>

  <script src="//cdn.jsdelivr.net/gh/highlightjs/cdn-release@10.0.0/build/highlight.min.js"></script>
  <script>hljs.initHighlightingOnLoad();</script>
  
    <script>

/**
*  RECOMMENDED CONFIGURATION VARIABLES: EDIT AND UNCOMMENT THE SECTION BELOW TO INSERT DYNAMIC VALUES FROM YOUR PLATFORM OR CMS.
*  LEARN WHY DEFINING THESE VARIABLES IS IMPORTANT: https://disqus.com/admin/universalcode/#configuration-variables*/
/*
var disqus_config = function () {
this.page.url = PAGE_URL;  // Replace PAGE_URL with your page's canonical URL variable
this.page.identifier = PAGE_IDENTIFIER; // Replace PAGE_IDENTIFIER with your page's unique identifier variable
};
*/
(function() { // DON'T EDIT BELOW THIS LINE
var d = document, s = d.createElement('script');
s.src = 'https://airmedtrans-com.disqus.com/embed.js';
s.setAttribute('data-timestamp', +new Date());
(d.head || d.body).appendChild(s);
})();
</script>
<noscript>Please enable JavaScript to view the <a href="https://disqus.com/?ref_noscript">comments powered by Disqus.</a></noscript>
                            
  
  
    
  
</body>
</html>